Research Institute Brainclinics:
Applied Neuroscience, Neuromodulation and Personalized Medicine for ADHD and Depression.
Brainclinics was established in 2001 as a research institute specialized in Applied Neuroscience, Neuromodulation, and Personalized Medicine with a focus on ADHD and depression. More scientific backgrounds on Neurofeedback in ADHD and rTMS in depression can be found here. For more client related information on these topics also see the neuroCare Clinics website.
Brainclinics conducts applied brain research (Applied Neuroscience) using of techniques such as EEG and QEEG, Actigraphy, Event Related Potentials (ERPs) and neuropsychological assessments.
iSPOT study of ADHD and Depression
Currently Research Institute Brainclinics is one of the international groups involved in the iSPOT studies, which stands for International Study to Predict Optimised Treatment Response in ADHD (iSPOT-A) and Depression (iSPOT-D). This is the largest trial worldwide into the potential of Personalized Medicine also called Precision Medicine in more than 2000 depressed patients (who will be prescribed an antidepressant), and more than 500 children with ADHD prescribed with methylphenidate (eg Ritalin).
For the iSPOT-A study we are still seeking healthy children (boys) between 6-17 years of age (healthy children do not need to use medication). For more information see the section iSPOT.
In the "Applied Neuroscience" section the history of these techniques and a historical review on diagnosis and prognosis of ADHD and Depression are presented. The first section describes the history from EEG to QEEG. The second part further elaborates on the EEG as a biomarker or endophenotype, followed by a historical overview of neurophysiological studies in ADHD and depression and an overview of models and theories about the interpretation of EEG and QEEG. Finally, some EEG examples for subtypes can be found such as a Low-Voltage EEG and Beta spindles.
Personalized Medicine for ADHD and Depression
In the recent years Brainclinics has specialized to further explore the use of neurophysiological techniques in predicting treatment outcomes to different treatments such as psychostimulants (e.g. Ritalin), antidepressants (e.g. SSRIs), rTMS for depression and Neurofeedback in ADHD. This development is also called Personalized Medicine. Under the section Personalized Medicine and Neuromodulation, more information can be found on the current status of treatment efficacy in psychiatry and new developments in this area. In the section on ADHD a summary of the current state of research on Personalized Medicine in ADHD to various treatments is provided. In addition an explanatory model is proposed explaining how to interpret these different sub-types and how treatments for ADHD may be further improved based on this knowledge.
In the section on depression the current status of research on Personalized Medicine for Depression is summarized and two subtypes that predict non-response to antidepressant treatments are described. In this section the possibilities for other treatments for these so-called non-responders are also described. Finally, a specific EEG endophenotype associated with non-response to various conventional treatments such as psychostimulants, antidepressants and rTMS, namely the Alpha Peak Frequency individual (iAPF) is described. This endophenotype is described in more detail and suggestions for potential interventions that deserve further development are described.
Research, publications and education
For an overview of scientific publications, book chapters and books published by Brainclinics staff you can consult the Publications section or the Media section to read about the several media appearances of Brainclinics.
Furthermore, Brainclinics also supports in the neuroCare neuroCademy workshops and training courses.
Brainclinics presents new scientific results at IPEG conference
At October 26-30, researchers from Research Institute Brainclinics have presented the latest scientific results of ongoing research at the International Conference of “the International Pharmaco-EEG Society (IPEG)", which took place in Nijmegen, The Nethrlands this time.
Brain activity predicts personalized antidepressant treatment
Today results from the large multicenter randomized iSPOT-D study were published in Clinical Neurophysiology demonstrating that brain activity can assist in predicting antidepressant treatment outcome to commonly used antidepressant drugs. In addition, this study clearly demonstrated qualitative differences in brain activity between males and females with depression, with implications for predicting antidepressant treatment outcome.